MedTrace Logo

Effects of Yangxinshi Pills on the Exercise Tolerance Compared With Trimetazidine in Patients After PCI

NCT03809273 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 681

Last updated 2025-09-10

No results posted yet for this study

Summary

This study compared the effect of Yangxinshi on exercise tolerance of patients with percutaneous coronary intervention (PCI) for the first time with Trimetazidine.Half of participants will receive Yangxinshi and Trimetazidine mimic tablets in combination,While the other half will receive Trimetazidine and Yangxinshi mimic tablets.

Conditions

  • Percutaneous Coronary Intervention

Interventions

DRUG

Yangxinshi

Yangxinshi pill 3 pills /tid

DRUG

Trimetazidine

Trimetazidine 20mg/tid

DRUG

Yangxinshi mimic

Yangxinshi mimic tablets 3 pills /tid

DRUG

Trimetazidine mimic

Trimetazidine mimic tablets 20mg/tid

Sponsors & Collaborators

  • Shenyang Northern Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-01
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03809273 on ClinicalTrials.gov